Literature DB >> 6302489

A quantitative assessment of reinnervation in the polyneuropathies.

J P Ballantyne, S Hansen.   

Abstract

The severity of denervation and the extent of compensatory reinnervation in a number of neuromyopathies was investigated using our computer-assisted motor unit counting and subtraction techniques. Patients with the chronic neuropathies of diabetes mellitus, renal failure and alcoholism, the acute neuropathy of the Guillain-Barré syndrome, and the neuronopathies of motor neuron disease and Alzheimer's disease were studied. Reinnervation in the uremic and alcoholic neuropathies was poor, and considerably less than that found in diabetic neuropathy. In general, the neuronopathies showed better reinnervation than the chronic neuropathies. In the acute neuropathy of the Guillain-Barré syndrome, reinnervation continued over periods of up to 7 years from the onset of the illness. Within this group some patients showed poor reinnervation, whereas in others we found that all of the electrophysiological parameters studied returned to normal, with concomitant remodeling of previously large motor units to normal size as reinnervation progressed.

Entities:  

Mesh:

Year:  1982        PMID: 6302489

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes.

Authors:  Nizar Souayah; Joseph G Potian; Carmen C Garcia; Natalia Krivitskaya; Christine Boone; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

2.  Electromyographic permutation entropy quantifies diaphragmatic denervation and reinnervation.

Authors:  Christopher Kramer; Denis Jordan; Alexander Kretschmer; Veronika Lehmeyer; Kristine Kellermann; Stephan J Schaller; Manfred Blobner; Eberhard F Kochs; Heidrun Fink
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.